|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk.
|
30617256 |
2019 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
GWAS on family history of Alzheimer's disease.
|
29777097 |
2018 |
|
Low density lipoprotein cholesterol measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program.
|
30275531 |
2018 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association study of Alzheimer's disease.
|
22832961 |
2012 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.
|
21460841 |
2011 |
|
BLOOD GROUP--LUTHERAN NULL
|
0.100 |
CausalMutation
|
phenotype |
CLINVAR |
|
|
|
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
<b>Aim</b>: This review aims to compare the development, characteristics and validity of three widely used breast cancer screening belief tools (the Champion's Health Belief Model Scale [CHBMS], the Breast Module of a Cancer Awareness Measures [BCAM] and the Breast Cancer Screening Beliefs Questionnaire [BCSBQ]).
|
31298055 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Here we report a cancer-specific gene fusion between BCAM, a membrane adhesion molecule, and AKT2, a key kinase in the PI3K signaling pathway.
|
25733895 |
2015 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
To elucidate the detailed function of BCAM in malignant tumors, we established BCAM-expressing hepatoma K2 cells.
|
24223164 |
2013 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
It also is necessary to investigate further the interaction between Lu/B-CAM and laminin a5 in pathological processes, including sickle cell disease and cancer.
|
16546822 |
2005 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Basal-cell adhesion molecule (B-CAM), a 90-kDa laminin receptor of the immunoglobulin superfamily, is induced in some epithelial malignancies.
|
15278364 |
2004 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
A unique gene encodes spliceoforms of the B-cell adhesion molecule cell surface glycoprotein of epithelial cancer and of the Lutheran blood group glycoprotein.
|
8781446 |
1996 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Patients with high Lu/BCAM expression showed a trend toward larger tumor size (p = 0.07) and lower disease-specific survival (p = 0.08), although not reaching statistical significance.
|
28841878 |
2017 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Further, we provide direct evidence that BCAM-AKT2 is translated into an in-frame fusion protein in the patient's tumor.
|
25733895 |
2015 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Moreover the soluble Lu/B-CAM in plasma of HCC patients was significantly decreased after resection of the tumor.
|
25051049 |
2014 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
We, also, found a correlation between decreased BCAM expression and tumor size or presence of metastasis.
|
23168236 |
2013 |
|
Anemia, Sickle Cell
|
0.050 |
Biomarker
|
disease |
BEFREE |
We investigated the molecular mechanisms responsible for the Lu/BCAM-mediated abnormal RBC adhesion to laminin in sickle cell disease (SCD) and HS.
|
20655789 |
2010 |
|
Anemia, Sickle Cell
|
0.050 |
Biomarker
|
disease |
BEFREE |
Aggregation of mononuclear and red blood cells through an {alpha}4{beta}1-Lu/basal cell adhesion molecule interaction in sickle cell disease.
|
20562314 |
2010 |
|
Anemia, Sickle Cell
|
0.050 |
Biomarker
|
disease |
BEFREE |
The Lu/BCAM adhesion glycoproteins were first identified as laminin-10/11 erythroid receptors involved in RBC adhesion to endothelium in sickle cell anemia.
|
18948049 |
2008 |
|
Anemia, Sickle Cell
|
0.050 |
Biomarker
|
disease |
BEFREE |
It also is necessary to investigate further the interaction between Lu/B-CAM and laminin a5 in pathological processes, including sickle cell disease and cancer.
|
16546822 |
2005 |
|
Anemia, Sickle Cell
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Red blood cells from patients with sickle cell disease (SS RBC) adhere to laminin and over-express the high-affinity laminin receptor basal cell adhesion molecule/Lutheran protein (B-CAM/LU).
|
14755370 |
2004 |
|
Anemia, Sickle Cell
|
0.050 |
Biomarker
|
disease |
LHGDN |
Red blood cells from patients with sickle cell disease (SS RBC) adhere to laminin and over-express the high-affinity laminin receptor basal cell adhesion molecule/Lutheran protein (B-CAM/LU).
|
14755370 |
2004 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
We demonstrated that expression of B-CAM is very weak, if detectable at all, in normal epidermis but is strongly induced in both basal cell carcinomas and squamous cell carcinomas of the skin, and most pronounced at the basal surface of the tumor nests.
|
15278364 |
2004 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
<b>Aim</b>: This review aims to compare the development, characteristics and validity of three widely used breast cancer screening belief tools (the Champion's Health Belief Model Scale [CHBMS], the Breast Module of a Cancer Awareness Measures [BCAM] and the Breast Cancer Screening Beliefs Questionnaire [BCSBQ]).
|
31298055 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Here we report a cancer-specific gene fusion between BCAM, a membrane adhesion molecule, and AKT2, a key kinase in the PI3K signaling pathway.
|
25733895 |
2015 |